Saifeddine Mahmoud, Seymour Michelle L, Xiao Yu-Pei, Compton Steven J, Houle Steeve, Ramachandran Rithwik, MacNaughton Wallace K, Simonet Serge, Vayssettes-Courchay Christine, Verbeuren Tony J, Hollenberg Morley D
Department of Pharmacology & Therapeutics, University of Calgary Faculty of Medicine, 3330 Hospital Drive N.W., Calgary, Alberta, Canada.
Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3279-89. doi: 10.1152/ajpheart.00519.2007. Epub 2007 Aug 31.
In canine coronary artery preparations, the proteinase-activated receptor-2 (PAR(2)) activating peptides (PAR(2)-APs) SLIGRL-NH(2) and 2-furoyl-LIGRLO-NH(2) caused both an endothelium-dependent relaxation and an endothelium-independent contraction. Relaxation was caused at peptide concentrations 10-fold lower than those causing a contractile response. Although trans-cinnamoyl-LIGRLO-NH(2), like other PAR(2)-APs, caused relaxation, it was inactive as a contractile agonist and instead antagonized the contractile response to SLIGRL-NH(2). RT-PCR-based sequencing of canine PAR(2) revealed a cleavage/activation (indicated by underlines) sequence (SKGR/SLIGKTDSSLQITGKG) that is very similar to the human PAR(2) sequence (R/SLIGKV). As a synthetic peptide, the canine PAR-AP (SLIGKT-NH(2)) was a much less potent agonist than either SLIGRL-NH(2) or 2-furoyl-LIGRLO-NH(2), either in the coronary contractile assay or in a Madin-Darby canine kidney (MDCK) cell PAR(2) calcium signaling assay. In the MDCK signaling assay, the order of potencies was as follows: 2-furoyl-LIGRLO-NH(2) >> SLIGRL-NH(2) = trans-cinnamoyl-LIGRLO-NH(2) >> SLIGKT-NH(2), as expected for PAR(2) responses. In the coronary contractile assay, however, the order of potencies was very different: SLIGRL-NH(2) >> 2-furoyl-LIGRLO-NH(2) >> SLIGKT-NH(2), trans-cinnamoyl-LIGRLO-NH(2) = antagonist. Because of 1) the distinct agonist (relaxant) and antagonist (contractile) activity of trans-cinnamoyl-LIGRLO-NH(2) in the canine coronary contractile assays, 2) the different concentration ranges over which the peptides caused either relaxation or contraction in the same coronary preparation, and 3) the markedly distinct structure-activity profiles for the PAR-APs in the coronary contractile assay, compared with those for PAR(2)-mediated MDCK cell calcium signaling, we suggest that the canine coronary tissue possesses a receptor system for the PAR-APs that is distinct from PAR(2) itself.
在犬冠状动脉制剂中,蛋白酶激活受体-2(PAR(2))激活肽(PAR(2)-APs)SLIGRL-NH(2)和2-呋喃甲酰-LIGRLO-NH(2)既引起内皮依赖性舒张,也引起内皮非依赖性收缩。引起舒张的肽浓度比引起收缩反应的浓度低10倍。尽管反式肉桂酰-LIGRLO-NH(2)与其他PAR(2)-APs一样引起舒张,但它作为收缩激动剂无活性,反而拮抗对SLIGRL-NH(2)的收缩反应。基于RT-PCR的犬PAR(2)测序揭示了一个切割/激活(以下划线表示)序列(SKGR/SLIGKTDSSLQITGKG),该序列与人PAR(2)序列(R/SLIGKV)非常相似。作为一种合成肽,犬PAR-AP(SLIGKT-NH(2))在冠状动脉收缩试验或麦迪逊-达比犬肾(MDCK)细胞PAR(2)钙信号试验中,其激动剂活性比SLIGRL-NH(2)或2-呋喃甲酰-LIGRLO-NH(2)弱得多。在MDCK信号试验中,效力顺序如下:2-呋喃甲酰-LIGRLO-NH(2) >> SLIGRL-NH(2) = 反式肉桂酰-LIGRLO-NH(2) >> SLIGKT-NH(2),这是PAR(2)反应所预期的。然而,在冠状动脉收缩试验中,效力顺序非常不同:SLIGRL-NH(2) >> 2-呋喃甲酰-LIGRLO-NH(2) >> SLIGKT-NH(2),反式肉桂酰-LIGRLO-NH(2) = 拮抗剂。由于1)反式肉桂酰-LIGRLO-NH(2)在犬冠状动脉收缩试验中具有独特的激动剂(舒张)和拮抗剂(收缩)活性,2)在同一冠状动脉制剂中,这些肽引起舒张或收缩的浓度范围不同,3)与PAR(2)介导的MDCK细胞钙信号相比,PAR-APs在冠状动脉收缩试验中的结构-活性谱明显不同,我们认为犬冠状动脉组织拥有一种与PAR(2)本身不同的PAR-APs受体系统。